Difference between revisions of "Octreotide (Sandostatin)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "manufacturer. Instead" to "manufacturer. Instead")
m
Line 8: Line 8:
 
==Diseases for which it is used==
 
==Diseases for which it is used==
 
*[[Neuroendocrine tumors]]
 
*[[Neuroendocrine tumors]]
 +
*[[Pancreatic NET]]
 
*[[Thymoma]]
 
*[[Thymoma]]
  
Line 30: Line 31:
  
 
[[Category:Neuroendocrine tumor medications]]
 
[[Category:Neuroendocrine tumor medications]]
 +
[[Category:Pancreatic NET medications]]
 
[[Category:Thymoma medications]]
 
[[Category:Thymoma medications]]
  
 
[[Category:Drugs FDA approved in 1988]]
 
[[Category:Drugs FDA approved in 1988]]

Revision as of 21:03, 22 January 2018

General information

Class/mechanism: Long-acting octapeptide that suppresses multiple hormones and has physiologic actions similar to somatostatin. It suppresses LH response to GnRH, reduces splanchnic blood flow, and inhibits release of serotonin, gastrin, vasoactive intestinal peptide, secretin, motilin, pancreatic polypeptide, growth hormone, IGF-I (somatomedin C), glucagon, insulin, and TSH.[1][2][3]
Route: SC, IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

Also known as

  • Code name: SMS 201-995
  • Generic names: octreotide immediate release, octreotide IR, octreotide acetate
  • Brand names: Longastatina, Octrestatin, Octride, Okeron, Proclose, Samilstin, Sandostatin, Sandostatina, Sandostatine

References